This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, M. R. Articles by Joshi, I. Search for Related Content PubMed PubMed Citation Articles by Smith, M. R. Articles by Joshi, I.

Efficacy of Treatment with Antisense Oligonucleotides Complementary to Immunoglobulin Sequences of bcl-2/Immunoglobulin Fusion Transcript in a t(14;18) Human Lymphoma-scid Mouse Model¹

Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

In t(14;18)-positive lymphoma cells, bcl-2 is expressed from a fusion mRNA transcript containing the full coding sequence of bcl-2 and 3' immunoglobulin sequences. We reported previously that antisense oligodeoxyribonucleotides directed at the bcl-2 translational start site, as well as those targeted to immunoglobulin sequences 3' of the translocation breakpoint, down-regulate bcl-2 and inhibit growth of the t(14;18)-positive lymphoma line WSU-FSCCL in vitro. We have developed a scid mouse model with this human cell line and demonstrate that antisense oligodeoxyribonucleotides targeted to immunoglobulin c_µ sequences down-regulate bcl-2 protein expression and induce apoptosis of WSU-FSCCL cells in vivo. This leads to prolonged survival of the mice. Targeting non-oncogenic sequences outside of the breakpoints of fusion transcripts may be a clinically useful therapeutic strategy.

This article has been cited by other articles:

				M. R. Smith, F. Jin, and I. Joshi Bortezomib Sensitizes Non Hodgkin's Lymphoma Cells to Apoptosis Induced by Antibodies to Tumor Necrosis Factor Related Apoptosis-Inducing Ligand (TRAIL) Receptors TRAIL-R1 and TRAIL-R2 Clin. Cancer Res., September 15, 2007; 13(18): 5528s - 5534s. [Abstract] [Full Text] [PDF]

				T. Oshitari, P. Polewski, M. Chadda, A.-F. Li, T. Sato, and S. Roy Effect of Combined Antisense Oligonucleotides Against High-Glucose-and Diabetes-Induced Overexpression of Extracellular Matrix Components and Increased Vascular Permeability Diabetes, January 1, 2006; 55(1): 86 - 92. [Abstract] [Full Text] [PDF]

				M. R. Smith, F. Jin, and I. Joshi Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts Mol. Cancer Ther., December 1, 2004; 3(12): 1693 - 1699. [Abstract] [Full Text] [PDF]

				M. Ladetto, P. Corradini, S. Vallet, F. Benedetti, U. Vitolo, M. Martelli, M. Brugiatelli, P. Coser, A. Perrotti, I. Majolino, et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO) Blood, August 13, 2002; 100(5): 1559 - 1565. [Abstract] [Full Text] [PDF]

				R. Mohammad, Y. Abubakr, M. Dan, A. Aboukameel, C. Chow, A. Mohamed, N. Hamdy, and A. Al-Katib Bcl-2 Antisense Oligonucleotides Are Effective against Systemic but not Central Nervous System Disease in Severe Combined Immunodeficient Mice Bearing Human t(14;18) Follicular Lymphoma Clin. Cancer Res., April 1, 2002; 8(4): 1277 - 1283. [Abstract] [Full Text] [PDF]